Which of the following is NOT listed as a pharmacologic option for stimulant use disorder treatment?

• A. Bupropion
• B. Haloperidol
• C. Methylphenidate
• D. Modafinil

Answer: (B)

The key idea is recognizing which medications have been studied as pharmacologic options to help with stimulant use disorder. Bupropion, methylphenidate, and modafinil have all been explored as potential treatments because they interact with dopamine or related systems in ways that might reduce craving or withdrawal and support recovery. For example, bupropion’s dopaminergic and noradrenergic effects have shown some signal of benefit in cocaine dependence in limited studies; methylphenidate can blunt withdrawal and cravings by providing a controlled stimulant effect; modafinil has been associated with reduced use in some trials.

Haloperidol, however, is an antipsychotic used to treat agitation, delirium, or stimulant-induced psychosis rather than to treat the underlying stimulant use disorder itself. It does not address cravings or relapse risk in a proven, ongoing way and is not used as a maintenance therapy for stimulant dependence. Therefore, haloperidol is not listed as a pharmacologic option for treating stimulant use disorder.